NASDAQ:INSM - Insmed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$26.33 -2.14 (-7.52 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$28.47
Today's Range$26.08 - $29.18
52-Week Range$11.49 - $33.94
Volume1.14 million shs
Average Volume836,127 shs
Market Capitalization$2.18 billion
P/E Ratio-9.11
Dividend YieldN/A
Beta1.07

About Insmed (NASDAQ:INSM)

Insmed logoInsmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900

Debt

Debt-to-Equity Ratio0.70
Current Ratio20.01
Quick Ratio20.01

Price-To-Earnings

Trailing P/E Ratio-9.11
Forward P/E Ratio-6.58
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book5.59

Profitability

EPS (Most Recent Fiscal Year)($2.89)
Net Income$-192,640,000.00
Net MarginsN/A
Return on Equity-68.14%
Return on Assets-46.47%

Miscellaneous

Employees214
Outstanding Shares76,620,000

Insmed (NASDAQ:INSM) Frequently Asked Questions

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed, Inc. (NASDAQ:INSM) released its quarterly earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.07. View Insmed's Earnings History.

What price target have analysts set for INSM?

9 brokerages have issued twelve-month price targets for Insmed's stock. Their forecasts range from $17.00 to $54.00. On average, they expect Insmed's share price to reach $37.4444 in the next twelve months. View Analyst Ratings for Insmed.

Who are some of Insmed's key competitors?

Who are Insmed's key executives?

Insmed's management team includes the folowing people:
  • Mr. William H. Lewis, Pres, CEO & Director (Age 49)
  • Ms. Christine A. Pellizzari, Chief Legal Officer (Age 50)
  • Ms. S. Nicole Schaeffer, Chief People Strategy Officer (Age 50)
  • Dr. Eugene J. Sullivan M.D., FCCP, Chief Product Strategy Officer (Age 53)
  • Mr. Andrew T. Drechsler, Advisor (Age 46)

Has Insmed been receiving favorable news coverage?

News stories about INSM stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Insmed earned a media sentiment score of 0.22 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.40 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Insmed's major shareholders?

Insmed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (9.34%), Redmile Group LLC (2.83%), Foresite Capital Management II LLC (1.26%), Northern Trust Corp (1.25%), Nexthera Capital LP (1.20%) and Lord Abbett & CO. LLC (1.04%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Institutional Ownership Trends for Insmed.

Which institutional investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, C WorldWide Group Holding A S, Victory Capital Management Inc., Teacher Retirement System of Texas, Sei Investments Co., Legal & General Group Plc, California State Teachers Retirement System and American International Group Inc.. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr and Melvin Md Sharoky. View Insider Buying and Selling for Insmed.

Which institutional investors are buying Insmed stock?

INSM stock was acquired by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Foresite Capital Management II LLC, Nexthera Capital LP, Bellevue Group AG, PointState Capital LP, Lord Abbett & CO. LLC, California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for Insmed.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $26.33.

How big of a company is Insmed?

Insmed has a market capitalization of $2.18 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]


MarketBeat Community Rating for Insmed (INSM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  586
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insmed (NASDAQ:INSM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Insmed in the last 12 months. Their average twelve-month price target is $37.4444, suggesting that the stock has a possible upside of 42.21%. The high price target for INSM is $54.00 and the low price target for INSM is $17.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.782.752.86
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $37.4444$37.4444$37.25$36.7143
Price Target Upside: 42.21% upside53.59% upside25.97% upside22.34% upside

Insmed (NASDAQ:INSM) Consensus Price Target History

Price Target History for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/23/2018Credit Suisse GroupUpgradeNeutral ➝ Outperform$27.00 ➝ $31.00HighView Rating Details
3/21/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$39.00MediumView Rating Details
1/4/2018HC WainwrightReiterated RatingBuy$35.00MediumView Rating Details
1/4/2018Robert W. BairdReiterated RatingOutperform ➝ Positive$32.00 ➝ $42.00HighView Rating Details
11/3/2017CowenReiterated RatingBuy$54.00N/AView Rating Details
9/6/2017Stifel NicolausReiterated RatingBuy$27.00 ➝ $43.00HighView Rating Details
9/5/2017Leerink SwannBoost Price TargetOutperform$27.00 ➝ $36.00HighView Rating Details
9/5/2017Evercore ISIBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $40.00HighView Rating Details
6/11/2017CitigroupReiterated RatingNeutral$14.00 ➝ $17.00HighView Rating Details
8/21/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Insmed (NASDAQ:INSM) Earnings History and Estimates Chart

Earnings by Quarter for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) Earnings Estimates

2018 EPS Consensus Estimate: ($3.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.92)($0.92)($0.92)
Q2 20181($0.92)($0.92)($0.92)
Q3 20181($1.02)($1.02)($1.02)
Q4 20181($0.90)($0.90)($0.90)

Insmed (NASDAQ INSM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018Q1 2018($0.96)($0.89)ViewN/AView Earnings Details
2/23/2018Q4 2017($0.67)($0.85)ViewListenView Earnings Details
11/2/2017Q3 2017($0.69)($0.69)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.63)($0.72)ViewListenView Earnings Details
5/3/2017Q1 2017($0.60)($0.60)$0.30 millionViewListenView Earnings Details
2/23/2017Q316($0.89)($1.1040)$0.30 millionViewN/AView Earnings Details
11/3/2016Q216($0.59)($0.61)$0.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.59)ViewN/AView Earnings Details
5/5/2016Q1($0.56)($0.54)ViewN/AView Earnings Details
2/25/2016Q415($0.49)($0.51)ViewN/AView Earnings Details
11/6/2015Q315($0.48)($0.50)ViewN/AView Earnings Details
8/6/2015Q2($0.48)($0.47)ViewN/AView Earnings Details
5/7/2015Q115($0.49)($0.55)ViewN/AView Earnings Details
2/27/2015Q414($0.57)($0.36)ViewN/AView Earnings Details
11/6/2014Q314($0.51)($0.54)ViewN/AView Earnings Details
8/6/2014Q214($0.50)($0.59)ViewN/AView Earnings Details
5/8/2014Q114($0.39)($0.36)ViewN/AView Earnings Details
3/6/2014Q413($0.45)($0.41)ViewN/AView Earnings Details
11/5/2013Q313($0.41)($0.46)ViewListenView Earnings Details
8/6/2013Q2 2013($0.32)($0.28)$5.38 million$11.50 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.46)($0.43)ViewListenView Earnings Details
3/18/2013Q4 2012($0.31)($0.49)ViewN/AView Earnings Details
11/7/2012Q312($0.42)($0.38)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.31)($0.39)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.34)($0.28)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.38)($0.28)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.28)($0.35)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.33)($0.40)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.32)($0.37)ViewN/AView Earnings Details
3/10/2011Q4 2010($0.10)($0.48)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.03)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.03)ViewN/AView Earnings Details
5/6/2010Q1 2010$0.01ViewN/AView Earnings Details
3/15/2010Q4 2009$0.10ViewN/AView Earnings Details
11/6/2009Q3 2009($0.01)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.13)ViewN/AView Earnings Details
5/13/2009Q1 2009$2.83ViewN/AView Earnings Details
3/11/2009Q4 2008($0.32)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.18)ViewN/AView Earnings Details
8/8/2008Q2 2008($0.38)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.40)ViewN/AView Earnings Details
3/4/2008Q4 2007($0.30)($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Insmed (NASDAQ:INSM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insmed (NASDAQ INSM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.88%
Insider Trading History for Insmed (NASDAQ:INSM)
Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Insmed (NASDAQ INSM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017Donald J Hayden JrDirectorSell15,000$32.50$487,500.0071,131View SEC Filing  
9/7/2017Donald J Hayden JrDirectorSell45,000$29.67$1,335,150.0071,131View SEC Filing  
9/6/2017Melvin Md SharokyDirectorSell50,000$27.37$1,368,500.00View SEC Filing  
5/31/2017Christine A PellizzariGeneral CounselBuy10,000$15.14$151,400.0027,300View SEC Filing  
12/15/2016Christine A PellizzariGeneral CounselBuy20,000$12.81$256,200.0010,000View SEC Filing  
12/14/2016Myrtle S PotterDirectorSell6,466$12.79$82,700.145,000View SEC Filing  
11/14/2016Andrew T DrechslerCFOSell45,000$14.67$660,150.0020,000View SEC Filing  
11/9/2016Orlov S Nicole SchaefferSVPSell68,774$11.95$821,849.3037,500View SEC Filing  
2/1/2016William LewisCEOBuy50,000$13.34$667,000.0096,972View SEC Filing  
9/2/2015Donald J. Hayden, Jr.DirectorSell25,000$24.06$601,500.0036,687View SEC Filing  
5/12/2015Mark QuigleyVPSell18,750$22.07$413,812.50View SEC Filing  
8/13/2014Melvin Md SharokyDirectorBuy88,889$11.25$1,000,001.25View SEC Filing  
11/1/2013William LewisCEOBuy5,233$14.28$74,727.24View SEC Filing  
7/22/2013Fmr LlcInsiderSell158,758$12.02$1,908,271.16View SEC Filing  
7/18/2013Fmr LlcInsiderSell310,227$11.49$3,564,508.23View SEC Filing  
7/15/2013Fmr LlcInsiderSell161,531$10.79$1,742,919.49View SEC Filing  
7/9/2013Fmr LlcInsiderSell146,599$10.01$1,467,455.99View SEC Filing  
7/3/2013Fmr LlcInsiderSell365,779$9.96$3,643,158.84View SEC Filing  
7/1/2013William LewisCEOBuy7,585$9.83$74,560.55View SEC Filing  
6/24/2013Fmr LlcInsiderSell50,000$12.00$600,000.00View SEC Filing  
6/20/2013Fmr LlcInsiderSell143,088$12.24$1,751,397.12View SEC Filing  
6/12/2013Fmr LlcInsiderSell85,758$13.00$1,114,854.00View SEC Filing  
6/6/2013Fmr LlcInsiderSell130,557$12.85$1,677,657.45View SEC Filing  
4/1/2013William LewisCEOBuy9,816$7.58$74,405.28View SEC Filing  
1/9/2013William LewisCEOBuy10,770$6.90$74,313.00View SEC Filing  
12/3/2012William LewisCEOBuy13,568$7.36$99,860.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insmed (NASDAQ INSM) News Headlines

Source:
DateHeadline
3 Things In Biotech, May 17: Insmeds Approval Chance, Pfizer Finally Proves Similar, Eagle Ascends3 Things In Biotech, May 17: Insmed's Approval Chance, Pfizer Finally Proves Similar, Eagle Ascends
seekingalpha.com - May 18 at 10:22 AM
Insmed (INSM) Names Leo Lee to BoardInsmed (INSM) Names Leo Lee to Board
www.streetinsider.com - May 18 at 10:22 AM
Blog Exposure - FDA Accepted for Review Insmed’s Marketing Application for ALIS in NTM Lung Disease Caused by MACBlog Exposure - FDA Accepted for Review Insmed’s Marketing Application for ALIS in NTM Lung Disease Caused by MAC
finance.yahoo.com - May 18 at 10:22 AM
Insmed Appoints Leo Lee to its Board of DirectorsInsmed Appoints Leo Lee to its Board of Directors
finance.yahoo.com - May 17 at 4:48 PM
BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease TreatmentBRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment
www.reuters.com - May 16 at 9:44 AM
Insmed (INSM) Announces FDA Acceptance for Filing of NDA for ALIS in NTM Lung Disease Caused by MACInsmed (INSM) Announces FDA Acceptance for Filing of NDA for ALIS in NTM Lung Disease Caused by MAC
www.streetinsider.com - May 16 at 9:44 AM
Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MACInsmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC
finance.yahoo.com - May 16 at 9:44 AM
Insmed (INSM) Stock Rating Upgraded by ValuEngineInsmed (INSM) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 10 at 8:37 PM
-$0.98 Earnings Per Share Expected for Insmed, Inc. (INSM) This Quarter-$0.98 Earnings Per Share Expected for Insmed, Inc. (INSM) This Quarter
www.americanbankingnews.com - May 7 at 3:30 AM
Insmed, Inc. (INSM) Expected to Post Q2 2018 Earnings of ($0.92) Per ShareInsmed, Inc. (INSM) Expected to Post Q2 2018 Earnings of ($0.92) Per Share
www.americanbankingnews.com - May 7 at 2:07 AM
Insmeds (INSM) CEO William Lewis on Q1 2018 Results - Earnings Call TranscriptInsmed's (INSM) CEO William Lewis on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 9:47 AM
Insmed (INSM) Issues Quarterly  Earnings Results, Beats Expectations By $0.07 EPSInsmed (INSM) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - May 3 at 5:38 PM
Todays Research Reports on Trending Tickers: Insmed and Arena PharmaceuticalsToday's Research Reports on Trending Tickers: Insmed and Arena Pharmaceuticals
finance.yahoo.com - May 3 at 9:21 AM
Edited Transcript of INSM earnings conference call or presentation 2-May-18 12:30pm GMTEdited Transcript of INSM earnings conference call or presentation 2-May-18 12:30pm GMT
finance.yahoo.com - May 3 at 9:21 AM
Insmed, Inc. (INSM) Given Average Rating of "Buy" by AnalystsInsmed, Inc. (INSM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 3 at 1:35 AM
Insmed (INSM) PT Raised to $56 at CowenInsmed (INSM) PT Raised to $56 at Cowen
www.streetinsider.com - May 2 at 4:30 PM
Form 10-Q INSMED Inc For: Mar 31Form 10-Q INSMED Inc For: Mar 31
www.streetinsider.com - May 2 at 4:30 PM
BRIEF-Insmed Reports Q1 Loss Per Share $0.89BRIEF-Insmed Reports Q1 Loss Per Share $0.89
www.reuters.com - May 2 at 9:25 AM
Insmed Reports First Quarter 2018 Financial Results and Provides Business UpdateInsmed Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 2 at 9:25 AM
Insmed: 1Q Earnings SnapshotInsmed: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 9:25 AM
Insmed (INSM) Rating Increased to Hold at Zacks Investment ResearchInsmed (INSM) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 1 at 7:52 AM
Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018
finance.yahoo.com - April 25 at 9:35 AM
Insmed (INSM) Set to Announce Quarterly Earnings on TuesdayInsmed (INSM) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 7:28 AM
Insmed Inc. (INSM) Has Climbed To A 1-Month HighInsmed Inc. (INSM) Has Climbed To A 1-Month High
www.nasdaq.com - April 23 at 4:25 PM
Insmed Shares To Outperform Through 2018 After Slow Start, Credit Suisse Says In UpgradeInsmed Shares To Outperform Through 2018 After 'Slow Start,' Credit Suisse Says In Upgrade
finance.yahoo.com - April 23 at 4:25 PM
Insmed (INSM) Raised to Outperform at Credit Suisse GroupInsmed (INSM) Raised to Outperform at Credit Suisse Group
www.americanbankingnews.com - April 23 at 8:46 AM
Zacks: Brokerages Anticipate Insmed, Inc. (INSM) Will Post Earnings of -$0.80 Per ShareZacks: Brokerages Anticipate Insmed, Inc. (INSM) Will Post Earnings of -$0.80 Per Share
www.americanbankingnews.com - April 20 at 1:26 AM
Insmed (INSM) Upgraded by Zacks Investment Research to BuyInsmed (INSM) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 19 at 9:40 PM
Insmeds (INSM) Buy Rating Reaffirmed at HC WainwrightInsmed's (INSM) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 14 at 10:35 AM
ValuEngine Lowers Insmed (INSM) to SellValuEngine Lowers Insmed (INSM) to Sell
www.americanbankingnews.com - April 13 at 1:37 PM
Insmed (INSM) Rating Increased to Hold at BidaskClubInsmed (INSM) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM
BidaskClub Downgrades Insmed (INSM) to Strong SellBidaskClub Downgrades Insmed (INSM) to Strong Sell
www.americanbankingnews.com - April 10 at 3:54 PM
Insmed (INSM): Moving Average Crossover AlertInsmed (INSM): Moving Average Crossover Alert
finance.yahoo.com - April 10 at 9:54 AM
Insmed (INSM) Lifted to "Buy" at ValuEngineInsmed (INSM) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 10 at 12:37 AM
Insmed (INSM) Rating Increased to Hold at ValuEngineInsmed (INSM) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM
Insmed, Inc. (INSM) Receives Average Recommendation of "Hold" from AnalystsInsmed, Inc. (INSM) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 8 at 1:30 AM
-$0.81 Earnings Per Share Expected for Insmed, Inc. (INSM) This Quarter-$0.81 Earnings Per Share Expected for Insmed, Inc. (INSM) This Quarter
www.americanbankingnews.com - April 3 at 1:14 AM
Insmed (INSM) Rating Reiterated by HC WainwrightInsmed (INSM) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 1 at 7:35 PM
Insmed (INSM) Downgraded by Zacks Investment ResearchInsmed (INSM) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 1 at 7:00 PM
Insmed (INSM) Lowered to "Sell" at Zacks Investment ResearchInsmed (INSM) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 8:24 PM
Insmed (INSM) Lifted to "Buy" at Zacks Investment ResearchInsmed (INSM) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 1:28 PM
Insmed (INSM) Submits NDA to FDA for ALIS in NTM Lung Disease Caused by MACInsmed (INSM) Submits NDA to FDA for ALIS in NTM Lung Disease Caused by MAC
www.streetinsider.com - March 29 at 9:53 AM
Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MACInsmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC
finance.yahoo.com - March 29 at 9:53 AM
Insmed (INSM) Lifted to Buy at Zacks Investment ResearchInsmed (INSM) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 9:44 PM
Zacks Investment Research Lowers Insmed (INSM) to HoldZacks Investment Research Lowers Insmed (INSM) to Hold
www.americanbankingnews.com - March 27 at 1:16 PM
Insmed (INSM) Upgraded to Hold at BidaskClubInsmed (INSM) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - March 25 at 2:34 PM
Insmed (INSM) Downgraded to "Sell" at BidaskClubInsmed (INSM) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - March 24 at 10:48 AM
Commit To Buy Insmed At $15, Earn 15.8% Annualized Using Options - NasdaqCommit To Buy Insmed At $15, Earn 15.8% Annualized Using Options - Nasdaq
www.nasdaq.com - March 23 at 4:22 PM
Morgan Stanley Begins Coverage on Insmed (INSM)Morgan Stanley Begins Coverage on Insmed (INSM)
www.americanbankingnews.com - March 21 at 1:58 PM
Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan StanleyInsmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley
www.msn.com - March 21 at 10:40 AM

SEC Filings

Insmed (NASDAQ:INSM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insmed (NASDAQ:INSM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insmed (NASDAQ INSM) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.